Cyclic AMP-specific phosphodiesterase inhibitors

A compound having the formula

• wherein R1 is hydrogen, lower alkyl, bridged alkyl, aryl, heteroaryl, cycloalkyl, a 5- or 6-membered saturated heterocyclic, C1-3alkylenecycloalkyl, aryl- or heteroaryl-substituted propargyl, aryl- or heteroaryl-substituted allyl, or halocycloalkyl;
• R2 is hydrogen, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C1-3alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, aralkyl, alkaryl, heteroaralkyl, or heteroalkaryl;
• R3 is morpholinyl or piperizinyl;
• R4 is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;
• R5 is lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;
• R6 is hydrogen, lower alkyl, or C(═O)R7;
• R7 is lower alkyl, branched or unbranched, or aryl, either optionally substituted with one or more of RO8, NR8R9, or SR8;
• and
• R8 and R9, same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, heteroalkaryl, and aralkyl, or R8 and R9 together form a 4-membered to 7-membered ring;
• R10 is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, C(═O)alkyl, C(═O)cycloalkyl, C(═O)aryl, C(═O)Oalkyl, C(═O)Ocycloalkyl, C(═O)aryl, CH2OH, CH2Oalkyl, CHO, CN, NO2, or SO2R11;
• and
• R11 is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR8R9.